Januvia Re-examination Study (MK-0431-181)

• Status: Completed
• Trial end date: 2013-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The objectives of this survey are: 1) To examine the safety/efficacy profile of Januvia in Korean participants, and 2) To identify factors that might have an influence on the safety and efficacy profile of Januvia in Korean participants.

Post-marketing surveys are not considered applicable clinical trials and thus the results of this survey will not be posted at its conclusion. The results will be submitted to public health officials as required by applicable national and international laws.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Insulin; Insulin, Globin Zinc; Sitagliptin Phosphate

Criteria

Inclusion Criteria:

• Type 2 Diabetes Mellitus

• Treated With Januvia within local label for the first time

Exclusion Criteria:

• Contraindication to Januvia according to the local label

• Treated with Januvia before contract and out of enrollment period

Inclusion criteria for long-term surveillance

• Treated with Januvia for more than or equal to 24 weeks